window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Alzheimer’s Disease

  • Clinical Development,Neurosciences,Partnerships & Funding,Research & Development

    AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease

    AC Immune has amended its collaboration agreement with Eli Lilly [...]

    April 7, 2026
  • Biotech,Clinical Development,Clinical Trials,Drug Development,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

    AC Immune has initiated a Phase 1 trial of its [...]

    February 24, 2026
  • Biotech,Central Nervous System,Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Rare Diseases

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    January 20, 2026
  • Artificial Intelligence,Digital Health,Healthcare leadership,Medical devices,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    From awareness to action: Linus Health drives next era of early brain health detection

    Linus Health is accelerating its efforts in early brain health [...]

    January 19, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Digital Health,Neurosciences,Research & Development

    Linus Health to present AI-driven brain health research at CTAD 2025

    Linus Health, an AI-driven brain health company focused on early [...]

    November 20, 2025
  • Central Nervous System,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Porosome reconstitution therapy reverses Alzheimer’s pathology in human brain organoids

    Porosome Therapeutics has reported preclinical results showing that restoring porosome [...]

    November 18, 2025
  • Clinical Trials,Pharmaceuticals and therapeutics

    Galimedix completes phase 1 trial of oral Alzheimer’s drug GAL-101

    Galimedix Therapeutics has completed a phase 1 study of its [...]

    September 14, 2025
  • Clinical Development,Patient Centricity,Precision medicine,Real world evidence,Research & Development

    New Alzheimer’s guideline recommends blood biomarkers for more accessible diagnosis

    In a significant shift for Alzheimer’s care, the Alzheimer’s Association [...]

    July 31, 2025
  • Clinical Development,Precision medicine,Rare Diseases,Real world evidence,Research & Development,Technology and platforms

    Nautilus and the Allen Institute partner to map tau proteoforms in Alzheimer’s disease research

    Nautilus Biotechnology has announced a new collaboration with the Allen [...]

    August 4, 2025
  • Clinical Development,Drug Development,Precision medicine,Research & Development,Technology and platforms

    AltPep data highlights potential of intranasal peptide for early-stage Alzheimer’s

    AltPep Corporation has presented new preclinical findings at the Alzheimer’s [...]

    July 28, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed
    Categories: Clinical Trials, Immunology, Oncology, Research & Development
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
  • European liver experts highlight rising MASLD burden at EASL symposium in Budapest
    Categories: Clinical studies, Gastroenterology, Healthcare leadership, Liver disease, Metabolic Diseases
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top